SEARCH

SEARCH BY CITATION

References

  • Asou, N., Adachi, K., Tamura, U., Kanamaru, A., Kageyama, S., Hiraoka, A., Omoto, E., Akiyama, H., Tsubaki, K., Saito, K., Kuriyama, K., Oh, H., Kitano, K., Miyawaki, S., Takeyama, U., Yamada, O., Nishikawa, K., Takahashi, M., Matsuda, S., Ohtake, H. & Ohno, R. (2001) Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG). Cancer Chemotherapy and Pharmacology, 48(Suppl. 1), 6571.
  • Au, W.Y., Chim, C.S., Lie, A.K., Liang, R. & Kwong, Y.L. (2002) Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. British Journal of Haematology, 117, 130132.
  • Au, W.Y., Lie, A.K., Chim, C.S., Liang, R., Ma, S.K., Chan, C.H., Mak, Y.K., Chen, Y.T., So, C.C., Yeung, Y.M., Yip, S.F., Wong, L.G., Chan, J.C., Liu, S.Y. & Kwong, Y.L. (2003a) Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia. Annals of Oncology, 14, 752757.
  • Au, W.Y., Kumana, C.R., Kou, M., Mak, R., Chan, G.C., Lam, C.W. & Kwong, Y.L. (2003b) Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood, 102, 407408.
  • Au, W.Y., Fung, A., Ma, E.S., Liang, R. & Kwong, Y.L. (2004) Low frequency of FLT3 gene internal tandem duplication and activating loop mutation in therapy related acute myeloid leukemia and myelodysplastic syndrome. Cancer Genetics and Cytogenetics, 149, 169172.
  • Candoni, A., Damiani, D., Michelutti, A., Masolini, P., Michieli, M., Michelutti, T., Geromin, A. & Fanin, R. (2003) Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia. European Journal of Haematology, 71, 18.
  • Chim, C.S., Kwong, Y.L., Liang, R., Chu, Y.C., Chan, C.H., Chan, L.C., Wong, K.F. & Chan, T.K. (1996) All-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL). Hematological Oncology, 14, 147154.
  • Chim, C.S., Wong, S.Y. & Kwong, Y.L. (2003) Aberrant gene promoter methylation in acute promyelocytic leukaemia: profile and prognostic significance. British Journal of Haematology, 122, 571578.
  • Gilliland, D.G. (2003) FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors. Best Practice and Research in Clinical Haematology, 16, 409417.
  • Grimwade, D., Howe, K., Langabeer, S., Burnett, A., Goldstone, A. & Solomon, E. (1996) Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse. Leukemia, 10, 6166.
  • Grimwade, D., Gale, R., Hills, R., Kottaridis, P., Swirsky, D., Gilkes, A., Nugent, E., Mills, K., Wheatley, K., Solomon, E., Burnett, A. & Lynch, A. (2003) The relationship between FLT3 mutation status, biological characteristics and outcome in patients with acute promyelocytic leukaemia. Blood, 102 (abstract no. 334).
  • Hiorns, L.R., Swansbury, G.J., Mehta, J., Min, T., Dainton, M.G. & Treleaven, J. (1997) Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. British Journal of Haematology, 96, 314321.
  • Hu, J., Shen, Z.X., Sun, G.L., Chen, S.J., Wang, Z.Y. & Chen, Z. (1999) Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution. International Journal of Hematology, 70, 248260.
  • Jurcic, J.G., Nimer, S.D., Scheinberg, D.A., DeBlasio, T., Warrell, Jr, R.P., Miller, Jr, W.H. (2001) Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. Blood, 98, 26512656.
  • Kainz, B., Heintel, D., Marculescu, R., Schwarzinger, I., Sperr, W., Le, T., Weltermann, A., Fonatsch, C., Haas, O.A., Mannhalter, C., Lechner, K. & Jaeger, U. (2002) Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16). Hematology Journal, 3, 283289.
  • Kiyoi, H., Naoe, T., Yokota, S., Nakao, M., Minami, S., Kuriyama, K., Takeshita, A., Saito, K., Hasegawa, S., Shimodaira, S., Tamura, J., Shimazaki, C., Matsue, K., Kobayashi, H., Arima, N., Suzuki, R., Morishita, H., Saito, H., Ueda, R. & Ohno, R. (1997) Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia, 11, 14471452.
  • Kwong, Y.L., Wong, K.F. & Chan, T.K. (1995) Trisomy 8 in acute promyelocytic leukaemia: an interphase study by fluorescence in situ hybridization. British Journal of Haematology, 90, 697700.
  • Kwong, Y.L., Au, W.Y., Chim, C.S., Pang, A., Suen, C. & Liang, R. (2001) Arsenic trioxide- and idarubicin-induced wremissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study. American Journal of Hematology, 66, 274279.
  • Lee, J.J., Cho, D., Chung, I.J., Cho, S.H., Park, K.S., Park, M.R., Ryang, D.W. & Kim, H.J. (2003) CD34 expression is associated with poor clinical outcome in patients with acute promyelocytic leukemia. American Journal of Hematology, 73, 149153.
  • Ma, E.S., Au, W.Y., Wan, T.S., Kwong, Y.L. & Chan, L.C. (2000) Translocation (15;17)(q22;q21) not associated with acute promyelocytic leukemia and negative for PML/RARa rearrangement. Haematologica, 85, 768769.
  • Murray, C.K., Estey, E., Paietta, E., Howard, R.S., Edenfield, W.J., Pierce, S., Mann, K.P., Bolan, C. & Byrd, J.C. (1999) CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? Journal of Clinical Oncology, 17, 293297.
  • Noguera, N.I., Breccia, M., Divona, M., Diverio, D., Costa, V., DeSantis, S., Avvisati, G., Pinazzi, M.B., Petti, M.C., Mandelli, F. & Lo Coco, F. (2002) Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia, 16, 21852189.
  • Pantic, M., Novak, A., Marisavljevic, D., Djordjevic, V., Elezovic, I., Vidovic, A. & Colovic, M. (2000) Additional chromosome aberrations in acute promyelocytic leukemia: characteristics and prognostic influence. Medical Oncology, 17, 307313.
  • Shih, L.Y., Kuo, M.C., Liang, D.C., Huang, C.F., Lin, T.L., Wu, J.H., Wang, P.N., Dunn, P. & Lai, C.L. (2003) Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer, 98, 12061216.
  • Tallman, M.S., Andersen, J.W., Schiffer, C.A., Appelbaum, F.R., Feusner, J.H., Woods, W.G., Ogden, A., Weinstein, H., Shepherd, L., Willman, C., Bloomfield, C.D., Rowe, J.M. & Wiernik, P.H. (2002) All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood, 100, 42984302.
  • Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schakel, U., Platzbecker, U., Wermke, M., Bornhauser, M., Ritter, M., Neubauer, A., Ehninger, G. & Illmer, T. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 43264335.
  • Wang, Z.Y. (2003) Ham-wasserman lecture: treatment of acute leukemia by inducing differentiation and apoptosis. In: Hematology, pp. 113. American Society of Hematology Education Program.
  • Whitman, S.P., Archer, K.J., Feng, L., Baldus, C., Becknell, B., Carlson, B.D., Carroll, A.J., Mrozek, K., Vardiman, J.W., George, S.L., Kolitz, J.E., Larson, R.A., Bloomfield, C.D. & Caligiuri, M.A. (2001) Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Research, 61, 72337239.